The treatment staved off cancer for seven of eight patients with a condition where the odds are rarely that good.
Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint in a Phase 2 cohort of ...
New long-term clinical data for BioNTech's personalized mRNA cancer vaccine has delivered a potentially paradigm-shifting result in one of oncology's most challenging diseases. Presented at the ...
Nearly all of the patients who responded to the a personalized mRNA pancreatic vaccine are still alive six years later.
Trastuzumab pamirtecan, being developed under a 2023 partnership between BioNTech and DualityBio, elicited a 44.1% overall ...
After decades of struggling to find a way to treat pancreatic cancer, researchers have developed several promising new drugs ...
Ben Sasse (R–Neb.), who previously served as president of the University of Florida, revealed in late December that he had ...
MAINZ, Germany, April 24, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data for selected assets from its diversified oncology pipeline, including mRNA cancer ...
BioNTech, a biotech company best known for its successful development of a messenger RNA Covid-19 vaccine, is acquiring fellow mRNA company CureVac in a $1.25 billion stock deal that brings together ...
Zacks Investment Research on MSN
BioNTech (BNTX) surges 6.1%: Is this an indication of further gains?
BioNTech SE Sponsored ADR (BNTX) shares ended the last trading session 6.1% higher at $111.6. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...
The world could be only a few years away from a cancer vaccine, according to the couple behind the Pfizer/BioNtech COVID-19 vaccine. "We feel that a cure for cancer or to changing cancer patients' ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results